Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269. doi: 10.6004/jnccn.2017.0023.


Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.

Publication types

  • Practice Guideline

MeSH terms

  • Antineoplastic Agents / supply & distribution
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / standards
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Asymptomatic Diseases
  • Chemotherapy, Adjuvant / methods
  • Chemotherapy, Adjuvant / standards
  • Humans
  • Immunoglobulins / blood
  • Magnetic Resonance Imaging
  • Maintenance Chemotherapy / methods
  • Maintenance Chemotherapy / standards
  • Medical Oncology / standards*
  • Multiple Myeloma / blood
  • Multiple Myeloma / diagnosis*
  • Multiple Myeloma / therapy*
  • Myeloma Proteins / analysis
  • Positron Emission Tomography Computed Tomography
  • Radiotherapy, Adjuvant / methods
  • Radiotherapy, Adjuvant / standards
  • Serologic Tests
  • Standard of Care
  • Stem Cell Transplantation / methods*
  • Stem Cell Transplantation / standards
  • Treatment Outcome


  • Antineoplastic Agents
  • Immunoglobulins
  • Myeloma Proteins
  • multiple myeloma M-proteins